Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class A and class C beta-lactamases are two major molecular classes of enzymes produced by bacteria that confer resistance to beta-lactam antibiotics (including penicillins, cephalosporins, and related drugs). Both are serine hydrolases: they utilize an active site serine to break the characteristic four-membered beta-lactam ring of these antibiotics, disabling their antibacterial activity. Class A beta-lactamases include enzymes such as TEM, SHV, and CTX-M, many of which are plasmid-encoded, spread easily, and may confer extended-spectrum resistance (ESBLs). They are often inhibited by clavulanic acid but can evolve inhibitor resistance. Class C beta-lactamases (often called AmpC enzymes) are typically chromosomally encoded cephalosporinases that confer resistance primarily to cephalosporins and are often not inhibited by traditional beta-lactamase inhibitors. Both enzyme classes use a conserved mechanism involving acylation of a serine residue, followed by hydrolysis of the beta-lactam ring, and play a critical role in global antibiotic resistance in clinically important Gram-negative bacteria.
Hydrolysis of beta-lactam ring: The enzyme attacks the amide bond of the beta-lactam ring, breaking antibiotic structure and inactivating antibacterial activity. Serine-based catalysis: Both A and C use a nucleophilic serine (Ser70) for acylation and breakdown of beta-lactam antibiotics.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactamase class A and class C (Class A β-lactamase (often abbreviated as Class A BL) and class C β-lactamase (Class C BL); there is no single unified abbreviation for both classes together.).